Shares of GRI Bio, Inc. (NASDAQ:GRI – Get Free Report) were down 2.8% during mid-day trading on Tuesday . The company traded as low as 0.43 and last traded at 0.45. Approximately 143,300 shares changed hands during trading, a decline of 77% from the average daily volume of 616,372 shares. The stock had previously closed at 0.46.
GRI Bio Trading Down 2.8 %
The stock has a market capitalization of $1.43 million, a PE ratio of -0.01 and a beta of -1.77. The firm has a 50 day moving average of 0.74 and a two-hundred day moving average of 3.34.
About GRI Bio
GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.
See Also
- Five stocks we like better than GRI Bio
- What is Forex and How Does it Work?
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Using the MarketBeat Stock Split Calculator
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What Do S&P 500 Stocks Tell Investors About the Market?
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.
